2022(第十一届)亚洲医药研发领袖峰会

2022(第十一届)亚洲医药研发领袖峰会

  • 时间:

    2022/03/10 08:00 ~ 2022/03/11 18:00

  • 人数:

    限额500人
  • 地点:

    上海士研咨询...

    查看地图
  • 主办:

    上海士研管理咨询有限公司

浏览(1604) 赞(4

距峰会还有

47

峰会内容


【峰会报名正式开放】|【Registration Opens】


第十一届亚洲医药研发领袖峰会峰会
The 11th Asia Pharma R&D Leaders


2022年3月10日(周四)- 3月11日(周五) | 上海
10nd -11rd March, 2022|Shanghai

以临床价值为导向,做真正的创新药!

Clinical Value Oriented,to Make the Real New Drug!

主办单位:上海士研管理咨询有限公司

Organizer: Shine Consultant International



【邀请函 | Inviting Letter】



新药研发九死一生,面对当前未被满足的临床需求,药企研发策略应当如何选择?热门靶点扎堆、研究高水平重复该如何破局?应如何共同构建新药研发体系与创新生态圈?

亚洲医药研发领袖峰会(APRL)是亚洲地区聚焦药物研发主题的高端战略峰会。每年一届的研发盛会已陪伴中国与全球药物研发领袖走过十载光阴。第十一届APRL2022将再度汇聚来自全球跨国药企、国内外生物技术公司、科研院所等机构新药研发顶尖专家,深度聚焦以临床价值为导向、以患者为中心的药物研发与创新,共同致力于提升临床开发效率,加快新药开发上市速度,积极探索差异化研发战略,推动创新药研发国际化,连接全球药物研发领袖,携手攻克人类医学难题,向未满足的临床需求!


In the face of unmet clinical needs, how should pharmaceutical companies choose their R&D strategies?How to break the current situation such as the gathering of popular targets and the research of high-level repetition? How to build a new drug R&D system and innovation ecosystem together?
The 11th Asia Pharma R&D Leaders (APRL) is a high-end strategic summit in Asia focusing on drug discovery and development. This annual R&D event has been accompanying Chinese and global drug development leaders for ten years.
The 11th APRL 2022 will once again bring together top experts in new drug R&D from global multinational pharmaceutical companies, domestic and international biotechnology companies, scientific research institutes and other institutions. APRL 2022 will focus on clinical value-oriented and patient-centered drug development and innovation,work together to improve the efficiency of clinical development, accelerate the speed of new drug development to market, actively explore differentiated R&D strategies, promote the internationalization of innovative drug development, and connect global drug R&D Leaders, work together to overcome human medical problems and unmet clinical needs!

【论坛基本形式 | Basic Format For Summit】

大会议程.jpg


【大会亮点 | Event Highlight】

大会亮点.jpg

  • Gathering global pharmaceutical R&D leaders and experts,Discuss thenew pattern of drug development strategy

  • In-depth analysis of early clinical studies of drugs,Construct differentiated development strategies for new drugs

  • Focus on Global Synchronization Strategy for New Drug,Explore the new journey of international clinical trials

  • Insights into the external innovation and cooperative R&D model, Synergy to meet new clinical needs

  • Targeting the direction of frontier research and development in the industry,Share new breakthroughs in drug research and development


【谁将参与 | Who should attend】


Brochure 中-3.jpg

Classified by Industries
  • Global Leading Pharma15%

  • Chinese Pharma13%

  • Biotech31%

  • Academic/Research Institute3%

  • Venture Capital/Fund14%

  • Law Firm & Consulting6%

  • CRO/CMO14%

  • Bio Cluster2%

  • Other2%

Classified by Titles

  • President/CEO/GM/CSO/CMO/CTO/Dean/Founder/Partner/ Managing Director35%

  • VP/Director(R&D/Clinical/Registration/External Innovation )45%

  • Others20%


【关键议题 | Key lssue】



• 以临床价值为导向:中国药物研发与监管科学之路
• 新药开发全球化:海外药品审评审批政策与监管环境
• 全球研发格局:抗肿瘤药物的研发前沿进展
• 圆桌讨论:构建研发生态圈:探索加速产学研协同创新
• 新药早期研究开发策略与关键挑战
• 源头创新:靶点开发与新型化合物筛选
• 转化医学在新药早期研究中的应用
• 圆桌讨论:从中国新到全球新,中国医药创新生态系统的构建
• 全球临床合作:国际多中心临床策略的构建与实践
• 创新药临床试验设计关键要素与重点考量
• 全球新药同步开发下的法规注册与风险管理思考
• 圆桌讨论:经验交流,全球临床试验的困境与实践案例分享
• 双特异性抗体开发的关键与难点解析
• 下一个千亿市场:ADC抗体偶联药物的开发进展
• 新冠“特效药”竞速:中和抗体治疗性药物研发进 展与突破
• 圆桌讨论: 抗体研发格局,抗体药物差异化开发与布局
• 小分子药物研发策略及案例分析
• 小分子新药开发中的CMC关键策略与考量
• 创新药商业化高质量转化策略探讨
• 圆桌讨论:全球赛场竞技,小分子药物研发的差异化战略与布局
• 细胞与基因治疗产品工艺开发策略分享
• 国产mRNA新冠疫苗研发突破与产业化
• 新型AAV基因疗法开发与创新化探索
• 圆桌讨论:产业化之路,细胞疗法的商业化策略分析
• 中国医药产业投资并购的新格局与新趋势
• 创新药企投融资:多方合作的策略与考量
• 跨国药企在中国:药物研发模式与创新生态圈
• 圆桌讨论:协同创新,外部研发创新模式的构建与案例分享
• Oriented by Clinical Value: The Science Road of China's Drug Development and Regulatory
• Globalization of New Drug Development: The Policies and Regulatory Environment of Overseas Drug Review and Approval
• The landscape of Global R&D: Frontier Progress in Anti-Tumor Drug R&D
• [Panel] Building a R&D Ecosystem: Exploring and Accelerating the Collaborative Innovation of Industry, University and Research
• Strategies and Key Challenges for Early Research and Development of New Drugs
• Source Innovation: Target Development and New Compound Screening
• Application of Translational Medicine in the Early Research of New Drugs
• [Panel] From Chinese New to Global New: Construction of China's Pharmaceutical Innovation Ecosystem
• Global Clinical Cooperation: The Construction and Practice of International Multi-Center Clinical Strategy
• Key Elements and Considerations of Innovative Drug Clinical Trial Design
Thoughts on Regulatory Registration and Risk Management under the Simultaneous Development of Global New Drugs
• [Panel] Experience Exchange: Dilemma of Global Clinical Trials and Practice Case Sharing
• Analysis of the Key and Difficult Points in the Development of Bispecific Antibody Drugs
• The Next 100 Billion Market: The Development of ADC Drugs
• Race of New Crown "Specific Drugs": Progress and Breakthroughs in Research and Development of Neutralizing Antibody Therapeutic Drugs
• [Panel] The Pattern of Antibody Research and Development : Differentiated Development and Layout of Antibody Drugs
• Strategy and Case Analysis of Small Molecule Drug Development
• CMC Key Strategies and Considerations in the Development of New Small Molecule Drugs
• Discussion on the High-Quality Transformation Strategy of Innovative Drug Commercialization
• [Panel] Competition in the Global Arena: Differentiated Strategy and Layout of Small Molecule Drug Research and Development
• Strategy Sharing of Cell and Gene Therapy Product Process Development
• Development Progress of China's mRNA COVID-19 Vaccine
• Development and Innovative Exploration of New AAV Gene Therapy
• [Panel] Road to Industrialization: Analysis of Commercialization Strategy of Cell Therapy
• The New Pattern and Trend of Investment and Mergers in China's Pharmaceutical Industry
• Investment and Financing of Innovative Pharmaceutical Companies: Strategies and Considerations for Multi-Party Cooperation
• Multinational Pharmaceutical Companies in China: Drug R&D Model and Innovation Ecosystem
• [Panel] Collaborative Innovation: Construction of External R&D Innovation Model and Case Sharing

【历届演讲嘉宾和VIP贵宾 | Previous Speakers and VIP 】

Brochure 中-4.jpg

Brochure 中-5.jpg

Brochure 中-6.jpg


【历届参会企业代表 | Part of Previous Attending Companies 】

1.jpg

2.jpg



【历届会议精彩瞬间 | Wonderful Moment】

Brochure 中-9.jpg


【联系我们 | Contact Us】

参会咨询和媒体合作请联系
For inquiries and media cooperation, please contact


Aili Li 李先生
TEL: (86 21) 6095 7201/13849919680(微信同号)
E-ma
il: aili.li@shine-consultant.com




研究员推荐

更多

峰会合作

如有意向建立峰会合作,请拨打电话或发邮件,期待与您洽谈

邮箱:qzhw@qianzhan.com

QQ:3299135616